AU2005328058B2 — Osmotic device containing amantadine and an osmotic salt
Assigned to Adamas Pharmaceuticals Inc · Expires 2012-02-02 · 14y expired
What this patent protects
The invention relates to osmotic devices containing a unitary core which comprises an amantadine salt and an osmotic salt, in which the two salts have a common ion. The amantadine release speed is modified from a first order release profile to a zero order, pseudo zero order or s…
USPTO Abstract
The invention relates to osmotic devices containing a unitary core which comprises an amantadine salt and an osmotic salt, in which the two salts have a common ion. The amantadine release speed is modified from a first order release profile to a zero order, pseudo zero order or sigmoidal release profile by increasing the quantity of osmotic salt in the core of the device. The osmotic device includes a semi-permeable membrane with a controlled porosity which can be adapted as required in order to co-operate with the osmotic salt in providing a pre-determined drug-release profile. The osmotic salt does not have to be covered and is mixed with the amantadine salt.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.